Neurological Outcomes in Patients With Ischemic Stroke Receiving Enoxaparin or Heparin for Venous Thromboembolism Prophylaxis | Zendy

Carlos S. Kase | Zendy; Gregory W. Albers | Zendy; Christopher Bladin | Zendy; Cesare Fieschi | Zendy; Alberto Alain Gabbai | Zendy; William O’Riordan | Zendy; Graham F. Pineo | Zendy

Open Access

Neurological Outcomes in Patients With Ischemic Stroke Receiving Enoxaparin or Heparin for Venous Thromboembolism Prophylaxis

Author(s) -

Carlos S. Kase,

Gregory W. Albers,

Christopher Bladin,

Cesare Fieschi,

Alberto Alain Gabbai,

William O’Riordan,

Graham F. Pineo

Publication year - 2009

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.109.555003

Subject(s) - medicine , modified rankin scale , stroke (engine) , incidence (geometry) , heparin , enoxaparin sodium , physical therapy , low molecular weight heparin , ischemic stroke , ischemia , mechanical engineering , physics , optics , engineering

The Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study demonstrated that enoxaparin was superior to unfractionated heparin (UFH) in preventing venous thromboembolism in patients with ischemic stroke and was associated with a small but statistically significant increase in extracranial hemorrhage rates. In this PREVAIL subanalysis, we evaluate the long-term neurological outcomes associated with the use of enoxaparin compared with UFH. We also determine predictors of stroke progression.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research